Univariate and multivariate linear regression analysis considering average RNFL thickness across all quadrants as dependent variable
| Variables | Univariate coefficient (95% CI) | Multivariate coefficient | VIF | t | p Value | 95% CI |
|---|---|---|---|---|---|---|
| Epilepsy duration | −0.16 (−0.27 to −0.06) | −0.17 | 1.04 | −3.01 | 0.003 | −0.27 to −0.06 |
| Intellectual disability | −4.49 (−8.38 to −0.59) | −3.95 | 1.03 | −2.02 | 0.048 | −7.87 to −0.04 |
| Drug resistance | −6.07 (−9.69 to −2.46) | −4.89 | 1.01 | −2.65 | 0.009 | −8.52 to −1.25 |
| Female sex | 4.19 (0.98 to 7.41) | – | – | – | – | – |
| Ethosuximide exposure | −7.07 (−13.23 to −0.90) | – | – | – | – | – |
| Phenytoin exposure | −4.58 (−8.00 to −1.16) | – | – | – | – | – |
| Primidone exposure | −8.68 (−15.66 to −1.69) | – | – | – | – | – |
| Sodium valproate exposure | −4.25 (−7.97 to −0.53) | |||||
| Topiramate exposure | −4.45 (−7.74 to −1.17) | |||||
| VNS implant | −11.07 (−17.64 to −4.51) | |||||
| Constant | 94.14 | 1.94 | 48.52 | <0.001 | 90.32 to 97.96 |
RNFL, retinal nerve fibre layer; VIF, variance inflation factor; VNS, vagus nerve stimulator.